Teva to appeal against invalidation of Copaxone patents

Teva will appeal against a decision which saw the invalidation of four patents covering its multiple sclerosis drug Copaxone (glatiramer acetate injection).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Teva suffers defeat as Copaxone claims invalidated

27 October 2017 The English High Court has invalidated two patent claims protecting Copaxone (glatiramer acetate), a billion-dollar drug marketed by Teva.

Big Pharma

Teva sues nine companies for Copaxone patent infringement

23 December 2016 Teva has filed a complaint against nine pharmaceutical companies including Dr Reddy's Laboratories, Sandoz and Mylan for alleged patent infringement over Copaxone, a treatment for patients with multiple sclerosis.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Teva to appeal against invalidation of Copaxone patents

More on this story

Editor's picks

Editor's picks

More features